Epidermal growth factor (EGF), present in saliva and gastric juice, is a potent mitogen and an important element of mucosal defence. Changes in salivary and gastric juice epidermal growth factor in response to non-steroidal antiinflammatory drug (NSAIDs) (0-41) ng/ml) but gastric juice EGF increased from 0-42 (0-12) nglml to 0-69 (0.14) ng/ml (p<005). This increased EGF could contribute to the increased cellular proliferation observed during NSAID ingestion and may represent an important mechanism underlying gastric mucosal adaptation. (Gut 1994; 35: 611- It is now well known that non-steroidal antiinflammatory drugs (NSAIDs) damage the gastroduodenal mucosa leading to mucosal erosion and ulceration.' They are also associated with an increased incidence of ulcer-related complications such as perforation.45 Endoscopic studies have shown gastric mucosal damage during the first four weeks of NSAID administration. These studies have also shown, however, that mucosal lesions may improve, and even heal completely, despite continued NSAID ingestion.F5 The mechanisms involved in this 'adaptation' of the gastric mucosa remain unclear. A number of factors are important in mucosal defence including prostaglandins, the mucusbicarbonate barrier, cellular regeneration, and blood flow."' The mechanisms underlying NSAID mucosal damage are complex but include depletion of mucosal prostaglandins and the direct toxic effect of NSAIDs on epithelial cells.'6"7 Studies on the process of adaptation have shown an increase in cellular regeneration, suggesting that this could represent one of the mechanisms underlying adaptation. 18 19 
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On initial examination mild chronic gastritis and Helicobacter pylori were found in four of the 10 placebo patients and two of five taking misoprostol. Only one patient who developed erosions was colonised with H pylori, and so this finding did not influence the results. There was no significant change on routine histological examination after NSAID ingestion.
SALIVARY EGF
There was no significant change in the salivary EGF concentration or output during the study (Table II) . It is interesting to note, however, that in this relatively small group of patients, those who developed erosions tended to have lower salivary EGF concentrations on entry to the study. The group of patients with subsequent normal endoscopies had an initial salivary EGF concentration of 3-56 (0-64) ng/ml compared with 1-75 (0 54) ng/ml in those who developed erosions (p=NS).
GASTRIC JUICE EGF
In those patients taking misoprostol there was no significant change in the concentration ofEGF in gastric juice: it was 0 33 (0 -12) ng/ml initially and 0-32 (0-08) ng/ml after two weeks NSAID ingestion (p=NS). In the group of 10 patients taking placebo, however, the concentration of EGF in gastric juice increased from 0-42 (0-12) ng/ml to 0-69 (0 14) ng/ml (p<005) (Figure) .
In the patients who developed erosions (n= 3), the EGF concentration increased from 0-15 
Discussion
This study shows an increase in gastric juice EGF concentrations in patients taking NSAIDs which could contribute to mucosal repair and adaptation. As there was no significant change in salivary EGF, which in normal circumstances is believed to be the main source of EGF in the stomach, and there was no evidence of increased duodenal reflux, the increased gastric EGF must come from elsewhere. It is unlikely to come from the blood as serum EGF concentrations are much lower than those of gastric juice and so mucosal damage and leakage of serum might be expected to reduce rather than increase gastric EGF. Another possibility is that it is produced in the stomach.
There NSAIDs,836 and so this mechanism may contribute even in those with endoscopically normal mucosa. The gastric mucosa, therefore, may respond to NSAID induced damage by EGF production, both from the epithelial cells and by the induction of stem cell lineages produced EGF. Further studies are needed to identify exactly where the increased EGF that we have demonstrated has come from. Morphological identification of EGF in the gastric mucosa, which we were technically unable to do in the present study, seems to be the logical way forward.
EGF in gastric juice has no effect on healthy intact mucosa as the EGF receptors are predominantly on the basal aspect of the epithelial cells.37 Mucosal 
